BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

160 related articles for article (PubMed ID: 24267733)

  • 1. Palpable ductal carcinoma in situ: analysis of radiological and histological features of a large series with 5-year follow-up.
    Sundara Rajan S; Verma R; Shaaban AM; Sharma N; Dall B; Lansdown M
    Clin Breast Cancer; 2013 Dec; 13(6):486-91. PubMed ID: 24267733
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Sentinel node procedure is warranted in ductal carcinoma in situ with high risk of occult invasive carcinoma and microinvasive carcinoma treated by mastectomy.
    Tunon-de-Lara C; Giard S; Buttarelli M; Blanchot J; Classe JM; Baron M; Monnier B; Houvenaeghel G
    Breast J; 2008; 14(2):135-40. PubMed ID: 18315691
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The use of radioactive iodine-125 seed localization in patients with non-palpable breast cancer: a comparison with the radioguided occult lesion localization with 99m technetium.
    van der Noordaa ME; Pengel KE; Groen E; van Werkhoven E; Rutgers EJ; Loo CE; Vogel W; Vrancken Peeters MJ
    Eur J Surg Oncol; 2015 Apr; 41(4):553-8. PubMed ID: 25707349
    [TBL] [Abstract][Full Text] [Related]  

  • 4. What should be the width of radiological margin to optimize resection of non-palpable invasive or in situ ductal carcinoma?
    Ouldamer L; Lechaux E; Arbion F; Body G; Vildé A
    Breast; 2014 Dec; 23(6):889-93. PubMed ID: 25456102
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinicopathologic, mammographic, and sonographic features in 1,187 patients with pure ductal carcinoma in situ of the breast by estrogen receptor status.
    Rauch GM; Kuerer HM; Scoggins ME; Fox PS; Benveniste AP; Park YM; Lari SA; Hobbs BP; Adrada BE; Krishnamurthy S; Yang WT
    Breast Cancer Res Treat; 2013 Jun; 139(3):639-47. PubMed ID: 23774990
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Outcomes for women with ductal carcinoma-in-situ and a positive sentinel node: a multi-institutional audit.
    Moore KH; Sweeney KJ; Wilson ME; Goldberg JI; Buchanan CL; Tan LK; Liberman L; Turner RR; Lagios MD; Cody Iii HS; Giuliano AE; Silverstein MJ; Van Zee KJ
    Ann Surg Oncol; 2007 Oct; 14(10):2911-7. PubMed ID: 17597346
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Predictors of invasive disease in breast cancer when core biopsy demonstrates DCIS only.
    Dillon MF; McDermott EW; Quinn CM; O'Doherty A; O'Higgins N; Hill AD
    J Surg Oncol; 2006 Jun; 93(7):559-63. PubMed ID: 16705731
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Optimal management of ductal carcinoma in situ of the breast.
    Sakorafas GH; Farley DR
    Surg Oncol; 2003 Dec; 12(4):221-40. PubMed ID: 14998563
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Sentinel lymph node biopsy in contralateral prophylactic mastectomy: are we overtreating? Experience at a tertiary care hospital.
    Kuwajerwala NK; Dekhne NS; Pentiak PA; Fend D; Callahan RE; Amine M; Lucia V; Swartz J
    Clin Breast Cancer; 2013 Aug; 13(4):287-91. PubMed ID: 23706482
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Microinvasive ductal carcinoma in situ: clinical presentation, imaging features, pathologic findings, and outcome.
    Vieira CC; Mercado CL; Cangiarella JF; Moy L; Toth HK; Guth AA
    Eur J Radiol; 2010 Jan; 73(1):102-7. PubMed ID: 19026501
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Radiological and pathological size estimations of pure ductal carcinoma in situ of the breast, specimen handling and the influence on the success of breast conservation surgery: a review of 2564 cases from the Sloane Project.
    Thomas J; Evans A; Macartney J; Pinder SE; Hanby A; Ellis I; Kearins O; Roberts T; Clements K; Lawrence G; Bishop H;
    Br J Cancer; 2010 Jan; 102(2):285-93. PubMed ID: 20051953
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Mammographically detected, clinically occult ductal carcinoma in situ treated with breast-conserving surgery and definitive breast irradiation.
    Solin LJ; McCormick B; Recht A; Haffty BG; Taylor ME; Kuske RR; Bornstein BA; McNeese M; Schultz DJ; Fowble BL; Barrett W; Yeh IT; Kurtz JM; Amalric R; Fourquet A
    Cancer J Sci Am; 1996; 2(3):158-65. PubMed ID: 9166516
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The locoregional recurrence post-mastectomy for ductal carcinoma in situ: Incidence and risk factors.
    Bannani S; Rouquette S; Bendavid-Athias C; Tas P; Levêque J
    Breast; 2015 Oct; 24(5):608-12. PubMed ID: 26277546
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Extensive pure ductal carcinoma in situ of the breast: identification of predictors of associated infiltrating carcinoma and lymph node metastasis before immediate reconstructive surgery.
    Guillot E; Vaysse C; Goetgeluck J; Falcou MC; Couturaud B; Fitoussi A; Fourchotte V; Laki F; Malhaire C; Sigal-Zafrani B; Sastre-Garau X; Bollet MA; Mosseri V; Reyal F
    Breast; 2014 Apr; 23(2):97-103. PubMed ID: 24388733
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prediction of underestimated invasiveness in patients with ductal carcinoma in situ of the breast on percutaneous biopsy as rationale for recommending concurrent sentinel lymph node biopsy.
    Schulz S; Sinn P; Golatta M; Rauch G; Junkermann H; Schuetz F; Sohn C; Heil J
    Breast; 2013 Aug; 22(4):537-42. PubMed ID: 23237921
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Occult breast lesion localization plus sentinel node biopsy (SNOLL): experience with 959 patients at the European Institute of Oncology.
    Monti S; Galimberti V; Trifiro G; De Cicco C; Peradze N; Brenelli F; Fernandez-Rodriguez J; Rotmensz N; Latronico A; Berrettini A; Mauri M; Machado L; Luini A; Paganelli G
    Ann Surg Oncol; 2007 Oct; 14(10):2928-31. PubMed ID: 17674108
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The relevance of occult axillary micrometastasis in ductal carcinoma in situ: a clinicopathologic study with long-term follow-up.
    Lara JF; Young SM; Velilla RE; Santoro EJ; Templeton SF
    Cancer; 2003 Nov; 98(10):2105-13. PubMed ID: 14601079
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Ductal carcinoma in situ: value of sentinel lymph node biopsy.
    Sakr R; Barranger E; Antoine M; Prugnolle H; Daraï E; Uzan S
    J Surg Oncol; 2006 Oct; 94(5):426-30. PubMed ID: 16967457
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The Influence of Hospital and Surgeon Factors on the Prevalence of Axillary Lymph Node Evaluation in Ductal Carcinoma In Situ.
    Coromilas EJ; Wright JD; Huang Y; Feldman S; Neugut AI; Chen L; Hershman DL
    JAMA Oncol; 2015 Jun; 1(3):323-32. PubMed ID: 26181180
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The radiological excision of high risk and malignant lesions using the INTACT breast lesion excision system. A case series with an imaging follow up of at least 5 years.
    Allen SD; Osin P; Nerurkar A
    Eur J Surg Oncol; 2014 Jul; 40(7):824-9. PubMed ID: 24742589
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.